Mizuho reaffirmed their buy rating on shares of Arcus Biosciences (NYSE:RCUS) in a research report released on Monday, AnalystRatings.com reports. Mizuho currently has a $22.00 price objective on the stock.
A number of other research firms also recently issued reports on RCUS. ValuEngine upgraded Arcus Biosciences from a hold rating to a buy rating in a report on Thursday, August 1st. Zacks Investment Research downgraded Arcus Biosciences from a buy rating to a hold rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $17.35.
Shares of NYSE:RCUS traded down $0.02 during mid-day trading on Monday, reaching $7.97. 54,579 shares of the stock were exchanged, compared to its average volume of 171,959. The company has a market cap of $366.42 million, a P/E ratio of -5.57 and a beta of 0.99. Arcus Biosciences has a one year low of $6.30 and a one year high of $13.77. The stock’s 50 day simple moving average is $8.33 and its 200-day simple moving average is $8.48.
Several large investors have recently bought and sold shares of RCUS. Aperio Group LLC bought a new position in shares of Arcus Biosciences during the second quarter worth about $32,000. Meeder Asset Management Inc. grew its stake in Arcus Biosciences by 672.9% in the third quarter. Meeder Asset Management Inc. now owns 4,939 shares of the company’s stock valued at $46,000 after purchasing an additional 4,300 shares in the last quarter. Susquehanna International Group LLP bought a new position in Arcus Biosciences in the second quarter valued at approximately $119,000. Athanor Capital LP bought a new position in Arcus Biosciences in the second quarter valued at approximately $126,000. Finally, Russell Investments Group Ltd. bought a new position in Arcus Biosciences in the second quarter valued at approximately $128,000. Institutional investors and hedge funds own 46.83% of the company’s stock.
About Arcus Biosciences
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Recommended Story: What is quantitative easing?
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.